Hong Kong Stock Market Surge | Keystone Pharmaceutical-B (02616.HK) climbs over 3% again, planning to raise 4.67 billion Hong Kong dollars through rights issue for use in clinical research and development such as CS2009.

According to the Zhitong Finance APP, China Resources Pharmaceutical Group-B (02616.HK) has risen by more than 3% again. As of the time of writing, it has increased by 2.9% to 5.33 Hong Kong dollars, with a trading volume of 51.7694 million Hong Kong dollars.